Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19
Status:
Completed
Trial end date:
2020-10-23
Target enrollment:
Participant gender:
Summary
The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and
20,000 deaths in France. To date, no treatment or vaccine has been successful.
Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent
virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal
decolonization.
24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an
experimental group (benefiting from povidone iodine decolonization) or a control group.
Patients in the experimental group will be asked to gargle with a 1% povidone-iodine
solution, spray their nose with the same antiseptic solution, and finally applied 10%
povidone-iodine cream in each nostril, all four times a day for five days. Patients will be
followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.